Trending Topics in Gastroenterology | GastroAGI

Basal Crypt Dysplasia in Barrett's Esophagus: GUT | July 2026

Introduction: Barrett's esophagus (BE) is the principal precursor of esophageal adenocarcinoma. Early detection of neoplastic transformation is essential for preventing cancer progression. This review discusses basal crypt dysplasia (CD), an emerging histological entity that may represent one of the earliest stages of dysplasia in BE. Why was this review needed? • Barrett's esophagus and esophageal adenocarcinoma continue to increase worldwide. • Conventional dysplasia assessment may miss early neoplastic changes confined to the crypt base. • Diagnostic criteria for crypt dysplasia remain inconsistent. • Better pathological recognition may improve early cancer detection. • The biological significance of crypt dysplasia requires clarification. Key Takeaways: • Crypt dysplasia is characterized by dysplastic changes confined to the basal crypts, with little or no involvement of the surface epithelium. • Molecular studies demonstrate that crypt dysplasia shares key genetic alterations, including TP53 mutations and chromosomal instability, with conventional low-grade and high-grade dysplasia. • High-grade crypt atypia should be recognized as true crypt dysplasia, whereas low-grade crypt atypia requires careful distinction from reactive inflammatory changes. • Inflammation, ulceration, and erosion should be excluded before diagnosing crypt dysplasia to avoid overdiagnosis. • Standardized grading into low-grade and high-grade crypt dysplasia offers a practical framework but still requires prospective validation. • Further studies are needed to determine the natural history, cancer progression risk, and interobserver reproducibility of crypt dysplasia. Clinical Impact: Recognition of crypt dysplasia may enable earlier identification of neoplastic transformation in Barrett's esophagus before conventional surface dysplasia becomes evident. As diagnostic criteria become standardized, crypt dysplasia may become an important addition to Barrett's pathology reporting and risk stratification. Bottom Line: Basal crypt dysplasia is an emerging early marker of neoplasia in Barrett's esophagus. Although not yet ready for universal adoption, growing molecular and pathological evidence suggests it may become an important component of future Barrett's surveillance and management.

High-Resolution Impedance Manometry after POEM: AJG | May 2026

Introduction: Assessing esophageal clearance after peroral endoscopic myotomy (POEM) is essential for evaluating treatment success in achalasia. Timed barium esophagram (TBE) is the current standard, but high-resolution impedance manometry (HRiM) may provide a radiation-free physiological alternative. Why was this study needed? Although TBE is widely used after POEM, it requires repeated radiographic imaging and does not assess esophageal function in real time. This study evaluated whether HRiM could accurately assess esophageal clearance and predict long-term clinical outcomes. What did the study show? • Both HRiM and TBE demonstrated significant improvement in esophageal clearance after POEM. • HRiM showed excellent reproducibility and strong correlation with clinical symptom improvement. • Residual bolus detected by HRiM at 3 months identified patients at increased risk of treatment failure at 12 months. • HRiM demonstrated higher specificity than TBE for predicting long-term POEM failure, while both tests showed excellent negative predictive value. • Findings were confirmed in an independent external validation cohort. Clinical Impact: HRiM provides a reliable physiological assessment of esophageal clearance after POEM and may reduce dependence on repeated radiographic studies. It can help identify patients who require closer follow-up or additional intervention. Take-Home Message: High-resolution impedance manometry is a reproducible and effective tool for evaluating esophageal clearance after POEM. Its excellent ability to exclude future treatment failure makes it a valuable addition to the long-term follow-up of patients with achalasia.

Magnetic Sphincter Augmentation Provides Durable GERD Control : Ann Surg | Jun 2026

Introduction: Magnetic sphincter augmentation (MSA) has emerged as an effective surgical option for patients with gastroesophageal reflux disease (GERD) who continue to experience symptoms despite medical therapy. By augmenting lower esophageal sphincter function while preserving physiologic swallowing and venting mechanisms, MSA offers a less disruptive alternative to traditional antireflux surgery. Although short- and intermediate-term outcomes have been favorable, robust long-term data have been limited. Problem Statement: For any implantable antireflux device, long-term durability, symptom control, dependence on acid-suppressive medications, and device-related complications are critical considerations. Questions remain regarding the sustainability of reflux control beyond five years and the frequency of device removal or adverse events over time. Summary: This FDA post-approval study provides important long-term evidence on the effectiveness and safety of magnetic sphincter augmentation in patients with GERD. At more than five years of follow-up, most patients experienced sustained and clinically meaningful improvement in reflux-related quality of life, with the vast majority remaining free from daily proton pump inhibitor use. Objective testing confirmed durable reflux control, demonstrating persistent normalization of esophageal acid exposure in a substantial proportion of patients. A notable advantage of MSA was preservation of physiologic functions such as belching and vomiting, which are often impaired after conventional fundoplication. Dysphagia remained uncommon and generally manageable. Device-related complications were infrequent, with erosion occurring rarely. However, approximately one in eight patients required device explantation during long-term follow-up. Reassuringly, most patients who underwent device removal achieved symptom resolution through explantation alone, conversion to fundoplication, or device replacement. These findings demonstrate that MSA provides durable long-term control of GERD symptoms and reduces dependence on acid-suppressive medication while maintaining favorable functional outcomes. Although a minority of patients may ultimately require device removal, the overall long-term safety and efficacy profile supports MSA as an established surgical option for appropriately selected patients with chronic GERD.

New Strategies Needed for Resistant H. pylori : Indian J Gastroenterol | Jun 2026

Introduction: Helicobacter pylori infection affects more than half of the global population and remains a major cause of peptic ulcer disease, gastric mucosal inflammation, and gastric cancer. Successful eradication is a cornerstone of gastrointestinal practice, yet treatment effectiveness has progressively declined worldwide because of increasing antibiotic resistance and challenges related to treatment adherence. These concerns have transformed H. pylori management into an evolving global public health issue. Problem Statement: The effectiveness of conventional eradication regimens is increasingly compromised by rising resistance to commonly used antibiotics, including macrolides, nitroimidazoles, and other key agents. In addition, poor antibiotic penetration into the gastric mucosa, bacterial biofilm formation, efflux pump activity, and the complexity of multidrug treatment regimens contribute to eradication failure. Marked geographic variation in resistance patterns further complicates the selection of optimal therapy. Summary: This review examines the growing challenge of antimicrobial resistance in H. pylori management and highlights the importance of region-specific treatment strategies. The authors emphasize that resistance patterns vary considerably across different parts of the world, making empirical treatment approaches increasingly unreliable. Consequently, local resistance epidemiology should play a greater role in guiding eradication regimens. Beyond traditional antibiotic combinations, the review explores several emerging approaches designed to overcome current limitations. Novel drug-delivery systems, including gastro-retentive formulations and nanotechnology-based therapies, aim to improve antibiotic concentration and retention at the gastric mucosa, potentially enhancing eradication success. The review also discusses non-antibiotic strategies that may reduce reliance on conventional antimicrobials and help mitigate further resistance development. These innovative approaches seek not only to improve eradication rates but also to address the biological mechanisms that allow H. pylori to persist despite therapy. Overall, the review underscores that future management of H. pylori infection will likely require a combination of antimicrobial stewardship, personalized regional treatment algorithms, and innovative therapeutic technologies. As resistance continues to rise globally, integrating these emerging strategies into clinical practice may become essential for maintaining effective eradication and reducing the long-term burden of H. pylori-related disease.

Vonoprazan–Tetracycline Dual Therapy Simplifies H. pylori Rescue Treatment : Gastroenterology | June 2026

Introduction: Helicobacter pylori Infection eradication after prior treatment failure remains a major therapeutic challenge due to increasing antibiotic resistance, poor tolerability of multidrug regimens and declining adherence rates. Simplified rescue strategies with improved safety and efficacy are therefore urgently needed. Problem Statement: Traditional Bismuth Quadruple Therapy is effective but frequently associated with complex dosing schedules, high adverse event burden and poor patient compliance. Whether a simplified vonoprazan-based dual regimen can achieve comparable rescue eradication rates with better tolerability remained uncertain. Summary: This prospective randomized controlled trial evaluated a simplified dual regimen combining Vonoprazan and tetracycline as rescue therapy for H. pylori infection in patients with at least one prior eradication failure. The study compared 14-day vonoprazan–tetracycline dual therapy against standard bismuth quadruple therapy in 350 patients. The dual regimen achieved eradication rates that were noninferior to bismuth quadruple therapy across both modified intention-to-treat and per-protocol analyses, with eradication rates exceeding 90%. Importantly, the simplified dual regimen demonstrated a major tolerability advantage. Treatment-emergent adverse events occurred far less frequently compared with quadruple therapy, and no patients discontinued treatment because of side effects. Adherence was also significantly higher with dual therapy, likely reflecting reduced pill burden, simplified scheduling and improved gastrointestinal tolerability. These findings are clinically important because rescue H. pylori therapy frequently fails not only because of antimicrobial resistance but also because patients struggle to complete complex multidrug regimens. The study further reinforces the growing role of vonoprazan-based therapy in modern H. pylori management. Unlike traditional proton pump inhibitors, vonoprazan provides rapid, potent and sustained acid suppression, potentially improving antibiotic stability and bacterial eradication efficacy. The results are especially relevant in regions with high clarithromycin and metronidazole resistance, where conventional salvage regimens often become increasingly difficult to optimize. The use of tetracycline is also noteworthy because resistance rates remain relatively low globally compared with other commonly used antibiotics. Clinically, the regimen offers an attractive rescue strategy that balances efficacy, simplicity and tolerability, which are critical determinants of real-world eradication success. The findings additionally support an evolving treatment paradigm in H. pylori management favoring streamlined, high-potency acid suppression combined with fewer antibiotics rather than increasingly complex multidrug combinations. Importantly, the open-label design represents a limitation, and the study population was derived from China, which may affect global generalizability because regional antimicrobial resistance patterns differ substantially. Further studies comparing this regimen against rifabutin-based and susceptibility-guided rescue therapies will be important to define its position within future treatment algorithms. Longer-term surveillance will also be needed to monitor emerging tetracycline resistance if widespread adoption occurs. Overall, this trial demonstrates that vonoprazan–tetracycline dual therapy is an effective, simplified and better-tolerated rescue regimen for H. pylori infection, offering eradication efficacy comparable to bismuth quadruple therapy while substantially improving safety and adherence.

H. pylori Eradication Reduces Cancer but Mortality Benefit Remains Fragile : Gastroenterology | June 2026

Introduction Helicobacter pylori Infection eradication is widely accepted as a key strategy for prevention of Gastric Cancer. Large meta-analyses have consistently shown reductions in gastric cancer incidence following eradication therapy, supporting global screening and treatment initiatives. Problem Statement Although eradication therapy appears to reduce gastric cancer mortality statistically, the robustness of this mortality benefit has remained uncertain. Conventional meta-analytic significance testing may overestimate certainty when outcomes are rare and vulnerable to small data perturbations. Summary This commentary applied a fragility index analysis to previously published randomized trial meta-analysis data evaluating the impact of H. pylori eradication on gastric cancer incidence and mortality. The fragility index provides a practical measure of statistical robustness by estimating how many event reclassifications would be required to convert a statistically significant result into a nonsignificant one. The analysis demonstrated a striking contrast between cancer incidence reduction and mortality benefit. The fragility index for gastric cancer incidence was robust at 53, whereas the fragility index for gastric cancer-associated mortality was only 4. In practical terms, the observed mortality benefit could lose statistical significance if only four deaths across nearly 60,000 participants were reclassified. This finding raises important methodological and clinical considerations. Rare-event outcomes such as gastric cancer mortality are particularly susceptible to sparse data bias, stochastic variation and minor classification errors. The authors emphasize that even very small inaccuracies in death attribution within registry-based or hospital-derived datasets could plausibly alter the mortality signal. Importantly, the analysis does not challenge the role of H. pylori eradication as a cancer-preventive strategy. Rather, it questions whether current evidence definitively proves a meaningful extension in overall survival. The distinction between preventing cancer occurrence and prolonging life is clinically important. Eradication may successfully delay or reduce gastric carcinogenesis while patients ultimately succumb to competing comorbidities, particularly in older or metabolically vulnerable populations. The commentary therefore reframes H. pylori eradication primarily as a disease-burden reduction strategy rather than a definitively life-prolonging intervention. From a public health perspective, this remains highly meaningful. Reducing gastric cancer incidence can decrease endoscopic workload, surgical intervention, healthcare costs and long-term morbidity even if mortality curves remain relatively unchanged. The discussion is particularly relevant for health systems considering population-based eradication programs, especially in resource-constrained settings where prioritization decisions require careful assessment of absolute benefit. The authors also highlight the importance of transparent communication in preventive medicine. Programs should emphasize reductions in cancer burden and healthcare utilization rather than overstating unproven survival advantages. Methodologically, the work illustrates the value of fragility analysis as a complementary tool alongside p-values, confidence intervals and effect estimates when interpreting large preventive trials. Clinically, the findings still support current guideline recommendations advocating H. pylori eradication to reduce gastric cancer incidence, particularly in high-prevalence regions. However, the commentary appropriately cautions against overinterpreting mortality reductions from statistically fragile data. Limitations include reliance on aggregated meta-analytic data and dependence on the quality of the underlying trials, several of which carried unclear or high risk of bias. Future studies evaluating all-cause mortality rather than gastric cancer-specific mortality may better clarify the broader survival impact of eradication therapy. Overall, this fragility analysis reinforces that H. pylori eradication is a statistically robust cancer-prevention strategy, while the currently observed mortality benefit remains quantitatively fragile and should be interpreted cautiously.

Vonoprazan Triple and Reverse Hybrid Regimens Outperform High-Dose Dual Therapy for H. pylori : AJG | May 2026

Introduction Helicobacter pylori Infection remains a major global cause of peptic ulcer disease, gastric adenocarcinoma and mucosa-associated lymphoid tissue lymphoma. Rising antimicrobial resistance, particularly to clarithromycin, has progressively reduced eradication success with conventional triple therapy. The introduction of Vonoprazan has renewed interest in simplified high-acid suppression regimens capable of improving eradication rates. Problem Statement The optimal first-line vonoprazan-based eradication strategy remains uncertain, particularly regarding whether simplified high-dose dual therapy can achieve efficacy comparable to more complex triple or hybrid regimens in regions with substantial antibiotic resistance. Summary This multicenter Taiwanese randomized trial compared three contemporary first-line eradication strategies for H. pylori infection: vonoprazan high-dose dual therapy, vonoprazan triple therapy and rabeprazole-based reverse hybrid therapy over 14 days. The study demonstrated that both vonoprazan triple therapy and rabeprazole reverse hybrid therapy achieved significantly superior eradication rates compared with vonoprazan high-dose dual therapy. Intention-to-treat eradication exceeded 89% with the triple and reverse hybrid regimens, whereas vonoprazan dual therapy achieved lower efficacy at approximately 84%. These findings are clinically important because simplified dual therapies have been increasingly promoted as antibiotic-sparing approaches intended to reduce antimicrobial exposure and resistance selection. However, the results suggest that dual therapy may be insufficient in regions with significant clarithromycin resistance or heavier bacterial burden. Notably, adverse event rates were relatively low and comparable across all treatment groups, indicating that the improved efficacy of the more intensive regimens was not offset by substantially worse tolerability. This supports the clinical practicality of triple and reverse hybrid approaches in routine first-line management. The study also identified several important predictors of eradication failure. Clarithromycin resistance emerged as a major determinant of treatment failure, reinforcing the continuing global challenge posed by antimicrobial resistance in H. pylori management. Poor medication adherence demonstrated the strongest association with eradication failure, highlighting the critical importance of patient education and regimen completion. Higher body weight additionally predicted treatment failure across regimens, an observation that may reflect altered pharmacokinetics, insufficient antibiotic exposure or larger intragastric bacterial burden. This raises important questions regarding whether weight-adjusted treatment strategies may eventually be necessary in selected populations. Mechanistically, vonoprazan’s potent and sustained acid suppression likely enhances antibiotic stability and bacterial susceptibility by maintaining higher intragastric pH compared with traditional proton pump inhibitors. Nevertheless, this pharmacologic advantage alone was insufficient to fully overcome antimicrobial resistance when dual therapy was used. The strong performance of the rabeprazole reverse hybrid regimen is also noteworthy. Hybrid therapies sequentially combine dual and quadruple-type approaches to maximize bacterial eradication while balancing antibiotic exposure, and this strategy continues to demonstrate robust efficacy in Asian populations. Clinically, the findings suggest that empiric vonoprazan dual therapy should be used cautiously in areas with moderate-to-high clarithromycin resistance. Vonoprazan triple therapy or reverse hybrid regimens currently appear more reliable for achieving acceptable first-line eradication thresholds. The study further reinforces the broader principle that modern H. pylori treatment strategies must increasingly integrate regional resistance epidemiology, adherence optimization and individualized regimen selection rather than relying on universally applied empiric protocols. Overall, this randomized multicenter trial demonstrates that vonoprazan triple therapy and rabeprazole reverse hybrid therapy provide superior first-line H. pylori eradication compared with vonoprazan high-dose dual therapy. The results emphasize the persistent impact of clarithromycin resistance and support continued preference for combination regimens capable of consistently achieving high eradication success.

BRTO and TIPS Outperform Cyanoacrylate for Secondary GV Bleeding Prevention : Meta-analysis | May 2026

Introduction Gastric Varices are associated with severe hemorrhage, high transfusion requirements and substantial mortality in patients with Cirrhosis. Compared with esophageal varices, gastric varices bleed less frequently but often more catastrophically. Secondary prophylaxis after an index bleed remains challenging, and optimal management strategies continue to evolve. Current therapeutic options include endoscopic cyanoacrylate injection (ECI), Balloon-Occluded Retrograde Transvenous Obliteration and Transjugular Intrahepatic Portosystemic Shunt, each with distinct physiologic consequences and complication profiles. Problem Statement There remains no universal consensus regarding the optimal secondary prophylactic modality for gastric variceal bleeding. Comparative data among ECI, BRTO and TIPS have been limited by heterogeneity, small trial sizes and inconsistent outcome reporting. Summary This comprehensive aggregate and individual patient data meta-analysis evaluated outcomes of BRTO and TIPS compared with endoscopic cyanoacrylate injection for prevention of recurrent gastric variceal bleeding in cirrhosis. The study incorporated data from both observational studies and randomized controlled trials, strengthening comparative assessment across multiple therapeutic approaches. The primary finding was that both BRTO and TIPS significantly reduced all-cause rebleeding compared with cyanoacrylate injection alone. BRTO demonstrated the greatest reduction in recurrent bleeding risk, while TIPS also provided substantial protection against rebleeding events. These findings reinforce the superior durability of portal hemodynamic interventions compared with local endoscopic obliteration alone. Importantly, however, improved bleeding control did not translate into a demonstrable overall survival advantage. This likely reflects the multifactorial nature of mortality in advanced cirrhosis, where outcomes are influenced not only by recurrent hemorrhage but also by liver failure, infection, renal dysfunction and other portal hypertensive complications. Distinct complication profiles emerged between the endovascular strategies. BRTO was associated with increased risk of new or worsening ascites. Mechanistically, this is biologically plausible because BRTO obliterates spontaneous portosystemic shunts, thereby increasing portal venous pressure and potentially exacerbating portal hypertensive fluid accumulation. Conversely, TIPS substantially increased the risk of Hepatic Encephalopathy. By diverting portal blood away from hepatic detoxification pathways, TIPS predisposes susceptible patients to ammonia accumulation and neurocognitive dysfunction, a well-recognized tradeoff of portal decompression. One particularly important observation was that benefits in bleeding reduction were most pronounced among patients with Child-Pugh class B cirrhosis. This suggests that patients with intermediate hepatic reserve may derive the greatest net benefit from aggressive endovascular secondary prophylaxis strategies, whereas more advanced disease may attenuate therapeutic gains. Clinically, the findings support a more individualized approach to gastric variceal secondary prophylaxis. BRTO may be particularly attractive in patients with prior encephalopathy or preserved ascites control, whereas TIPS may remain preferable in patients with severe portal hypertension-related complications requiring decompression beyond gastric variceal management alone. The study additionally highlights persistent limitations in the evidence base. Long-term outcomes remain incompletely characterized, definitions of rebleeding vary across studies and heterogeneity remains especially substantial for TIPS-related outcomes because of differences in stent type, portal pressure targets and patient selection. Importantly, the analysis reinforces the concept that gastric varices differ fundamentally from esophageal varices in anatomy, hemodynamics and therapeutic response. Management algorithms designed for esophageal varices cannot simply be extrapolated to gastric variceal disease. Overall, this meta-analysis demonstrates that BRTO and TIPS are superior to endoscopic cyanoacrylate injection for reducing recurrent gastric variceal bleeding in cirrhotic patients. However, treatment selection must balance bleeding prevention against portal hypertensive complications such as ascites and hepatic encephalopathy, emphasizing the need for individualized multidisciplinary decision-making and further long-term comparative studies.

Guideline Gaps in Paediatric H. pylori Care : Frontline Gastroenterol | May 2026

Introduction Helicobacter pylori infection remains an important paediatric gastrointestinal infection worldwide, yet its diagnosis and treatment in children differ substantially from adult practice. The joint ESPGHAN–NASPGHAN guidelines advocate a restrictive, endoscopy-based diagnostic strategy with culture-guided therapy and structured eradication confirmation to minimise inappropriate antibiotic exposure and resistance development. This multicentre UK audit evaluated real-world paediatric practice against current international recommendations. Problem Statement Despite established paediatric-specific guidance, diagnostic and therapeutic approaches to H. pylori infection in children frequently remain extrapolated from adult pathways. The extent of deviation from guideline-recommended testing, treatment duration and post-treatment follow-up in UK clinical practice has remained poorly characterised. Summary This retrospective multicentre audit analysed paediatric H. pylori testing practices across nine NHS trusts between April 2023 and June 2024. More than 1900 stool antigen tests performed in children aged ≤16 years were reviewed, of which 249 (13%) were positive. The mean age of tested children was 9.6 years. Most positive tests represented initial diagnosis (84%), while only 15% were performed for eradication confirmation. The study demonstrated widespread divergence from ESPGHAN–NASPGHAN recommendations across nearly all stages of care. Stool antigen testing was frequently used as a primary diagnostic tool in symptomatic children, particularly for abdominal pain, despite guidelines discouraging non-invasive “test-and-treat” strategies in paediatric populations. Abdominal pain was the most common indication for testing across both primary and secondary care settings, reflecting persistent misconceptions regarding the causal relationship between H. pylori and functional abdominal symptoms in children. Treatment practices also showed substantial inconsistency. Empirical eradication therapy was commonly prescribed without endoscopic confirmation or antimicrobial susceptibility testing. Importantly, 88% of first-line treatment regimens and 60% of re-treatment courses deviated from ESPGHAN–NASPGHAN recommendations, most commonly because of inappropriate antibiotic combinations or shortened treatment duration. These findings raise important antimicrobial stewardship concerns, particularly in the context of rising global clarithromycin and metronidazole resistance. Post-treatment follow-up was similarly suboptimal. Only 53% of children undergoing initial treatment and 64% receiving eradication therapy underwent follow-up stool antigen testing, and testing was frequently performed outside recommended timing windows. This inconsistency limits accurate eradication assessment and may contribute to persistent infection, recurrent symptoms and unnecessary repeated antibiotic exposure. The audit additionally highlighted variability between primary and tertiary care referral patterns, with symptom profiles and testing indications differing substantially across healthcare settings. Limited awareness of paediatric-specific guidelines, alongside continued reliance on adult management paradigms, likely contributed to these discrepancies. Overall, this important UK multicentre audit demonstrates major gaps between current paediatric H. pylori practice and international guideline standards. The findings underscore the need for harmonisation of UK national recommendations with ESPGHAN–NASPGHAN guidance, improved clinician education and stronger antimicrobial stewardship frameworks to promote evidence-based, standardised paediatric H. pylori management.

BSG/ACPGBI Advise Against Routine Tranexamic Acid in GI Bleeding : Frontline Gastroenterol | May 2026

Introduction Tranexamic acid has been widely used across trauma, surgical and hemorrhagic settings because of its antifibrinolytic effects and ability to stabilize clot formation. Earlier small studies suggested potential benefit in gastrointestinal bleeding, leading to interest in its use for acute upper and lower GI hemorrhage. Problem Statement Despite historical enthusiasm, uncertainty remained regarding the efficacy and safety of tranexamic acid in gastrointestinal bleeding, particularly in the era of modern endoscopic hemostasis, proton-pump inhibitors and contemporary supportive care. Clarification from major societies was required following publication of high-quality randomized evidence. Summary This position statement from the British Society of Gastroenterology and Association of Coloproctology of Great Britain and Ireland strongly advises against the routine use of tranexamic acid in acute upper or lower gastrointestinal bleeding. The recommendation is primarily based on the landmark HALT-IT trial, a large international randomized placebo-controlled study involving more than 12,000 patients with significant GI bleeding. HALT-IT demonstrated no reduction in bleeding-related mortality with tranexamic acid administration despite earlier smaller studies suggesting possible benefit. Importantly, the trial identified increased risks of venous thromboembolism and seizures among patients receiving tranexamic acid, raising significant safety concerns. The societies emphasize that earlier positive studies were methodologically weak and conducted before widespread use of modern endoscopic therapy and optimized acid suppression. Consequently, the position statement concludes that the overall risk–benefit profile does not support routine TXA use in GI bleeding. The document further states that any exceptionally rare off-guideline use should occur only after exhaustion of standard therapies, require senior consultant-level decision-making and be clearly documented within institutional governance systems. This statement is clinically important because tranexamic acid continues to be intermittently used in GI bleeding despite robust negative evidence. The guidance reinforces evidence-based deimplementation of ineffective interventions and highlights the importance of avoiding therapies associated with potential thrombotic harm in already vulnerable bleeding populations.